Teplinovivint

Teplinovivint is a potent wnt/β-catenin signaling pathway inhibitor. Teplinovivint has anti-inflammatory activity and has the potential for tendinopathy research. In Vitro Teplinovivint (compound 175; 0.0003-10 μM) inhibits Wnt/p-catenin activity in human colorectal cancecell line (SW480) in a dose-dependent manner (EC 50 =152.9 nM). Teplinovivint inhibits SW480 cells (EC 50 =25 nM) and primary human mesenchymal stem cells (hMSCs; EC 50 =10.377 μM). Teplinovivint (5.8, 10.8, 21.7, 41.7, 83.3, 166.6, 333.3, 750 nM) induced the expression of SCXA, TenacinC and Tenomodulin, in a dose-dependent manner with an EC 50 between 139-189 nM. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Teplinovivint (compound 175; 10 mg/ml; once daily for 21 days via topical application) causes amelioration of inflammation as well as tendon degeneration. Teplinovivint results in a decrease of aninflammatory plasma biomarker, KC/GRO in the Collagenase-induced Tendon Injury Model . Teplinovivint (1 mg/ml with 1% BA) has a T max of 1 hours in plasma . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet